Description:

E1105 Hypertension Status Form First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3DA5CD22-EF9E-0E6A-E044-0003BA3F9857

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3DA5CD22-EF9E-0E6A-E044-0003BA3F9857
Keywords:
  1. 8/26/12 8/26/12 -
  2. 8/8/14 8/8/14 - Martin Dugas
  3. 8/8/14 8/8/14 - Martin Dugas
  4. 12/16/14 12/16/14 - Martin Dugas
  5. 1/8/15 1/8/15 - Martin Dugas
  6. 8/7/15 8/7/15 - Martin Dugas
Uploaded on:

August 7, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Hypertension Status Form Breast Cancer E1105 NCT00520975

INSTRUCTIONS: After patient is off treatment, complete this form for each required follow-up report period (see forms submission schedule).

General information
Off Treatment Report Period (since registration)
Reporting Period
On Treatment Report Period (Maintenance 1 cycle = 3 weeks)
mmHg
mmHg
Anti-Hypertensive Drugs
Comments

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial